DSM Pharmaceuticals Appoints New CEO

Article

DSM Pharmaceutical Products appoints a new CEO and President.

DSM Pharmaceutical

Products, the contract manufacturing organization of Royal DSM, appointed Lukas Utiger, PhD as its new CEO and President, effective Oct. 1, 2013.

Headquartered in Parsippany, NJ, the DSM Pharmaceutical Products business group includes DSM Biologics/BioSolutions, DSM Pharma Chemicals, DSM Exclusive Synthesis & Intermediates, and DSM Pharmaceuticals with operations in the US, Europe, and Australia.

Utiger has 25 years of industry experience, managing both small- and large-molecule manufacturing, as well as research and development.

Prior to joining DSM, Utiger was responsible for Lonza’s Bioscience division, where for more than 10 years he also served on the executive committee for various divisions including the pharma contract manufacturing organization and nutrition.

Source:

DSM Pharmaceutical

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.